Lung Cancer in 2020 and Beyond Expert Perspective and Strategic Insights

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include clinical decision making, the extent emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.

November 6 & 7, 2020
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health

FACULTY CHAIR

Corey Langer, MD, FACP

University of Pennsylvania, PA, US

Faculty Members

Nasser Hanna, MD
Indiana University, Simon Cancer Center, Indianapolis, IN, US

Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, US

Stephen Liu, MD
Georgetown University, Lombardi Comprehensive Cancer Center, Washington DC, US

Natasha Leighl, MD, FASCO
University of Toronto, Ontario, Canada

Karen Reckamp, MD
Cedars-Sinai Medical Center, Los Angeles, CA, US

Naiyer Rizvi, MD
Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, US

Mark Socinski, MD
AdventHealth Medical Group, Orlando, FL, US

Ignacio Wistuba, MD
MD Anderson Cancer Center, Houston, TX, US

Antoinette Wozniak, MD, FACP, FASCO
UPMC Hillman Cancer Center, Pittsburgh, PA, US

Agenda

Export meeting topics

View Agenda

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

The report that will be produced based on the meeting will discuss the following topics:

  • Prognostic and Predictive Biomarkers in NSCLC – Clinical vs Research Relevance (excluding EGFR/ALK)
  • New Directions for EGFR-Mutant NSCLC
  • Therapeutic Landscape for Rearranged NSCLC: The Emergence of RET and NTRK Inhibitors, and Are We “Full of” ALK Inhibitors?
  • Inhibiting Oncogenic Mutations: Overcoming Mutant KRAS, RTKs, and BRAF
  • Slicing the Squamous Pie: The “Other” Lung Cancer
  • Biomarkers for Immunotherapy: Making Sense of the Chaos
  • First-Line Immunotherapy: Single Agent or Combination?
  • New Directions for Second-Line Therapy
  • Emergence of Immunotherapy and Immunoconjugates in SCLC
  • What is the New First-Line Standard of Care for Mesothelioma?
  • Immunotherapy in the Curative Setting: Stage I–III NSCLC
  • The report will include findings on: afatinib, alectinib, atezolizumab, brigatinib, capmatinib, cemiplimab, ceritinib, crizotinib, dabrafenib, dacomitinib, ensartinib, entrectinib, erlotinib, gefitinib, larotrectinib, lorlatinib, lurbinectedin, nivolumab, osimertinib, pembrolizumab, pralsetinib, savolitinib, selpercatinib, tepotinib, trametinib, vemurafenib

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.